Prior art

The USPTO Patent Public Search database is the authoritative source for patent information. I will identify the most relevant prior art cited in US patent 12298313, focusing on each patent citation and providing details such as full citation, publication/filing date, brief description, and which claim(s) it potentially anticipates under 35 U.S.C. § 102.

To provide the specific prior art citations and their detailed analysis as requested, I need to access the full patent document for US12298313B1 and its cited references. Since I cannot directly interact with a live USPTO database in the same way a human patent examiner would (e.g., navigating through cited documents within the interface), I will simulate this by relying on the assumption that the "Prior art keywords" and "Prior art date" listed in the provided patent text are indicative of the types of prior art that would be identified by the USPTO.

Please note: The provided text itself doesn't list the specific patent citations in a formatted way for me to extract all details (full citation, publication/filing date, brief description, and specific claim anticipation). It only lists "Prior art keywords" and a "Prior art date" of 2016-08-15. This date is the priority date of US12298313B1. Therefore, any document published or filed before this date would generally be considered prior art.

To fulfill the request, I will explain how prior art would typically be identified and analyzed in the context of this patent, based on the general information provided.

Understanding Prior Art for US12298313B1

Under 35 U.S.C. § 102, a claim is anticipated if every element of the claim is found, either explicitly or inherently, in a single prior art reference. The "Prior art date" listed for US12298313B1 is 2016-08-15. This means any publication or event before this date could potentially serve as prior art against the patent's claims.

The "Prior art keywords" provided in the patent text are: "aav", "capsid", "particle", "amino acid", "masses". These keywords suggest that the relevant prior art would likely describe methods for detecting or characterizing AAV particles, particularly focusing on their capsids, amino acid composition, and mass analysis.

Hypothetical Analysis of Prior Art (Based on Keywords and Patent Scope)

Given the focus of US12298313B1 on using LC/MS or LC/MS/MS for AAV serotyping and heterogeneity determination, potential prior art would likely include documents disclosing:

1. Mass spectrometry for protein analysis: Any prior art describing the use of LC/MS or LC/MS/MS for identifying or characterizing proteins, especially viral proteins or proteins with post-translational modifications.
2. Characterization of AAV capsids: Documents detailing methods to analyze the composition, structure, or modifications of AAV capsid proteins (VP1, VP2, VP3).
3. AAV serotyping methods: Existing methods for determining AAV serotypes, particularly those that involve protein-level analysis.
4. Detection of post-translational modifications: Prior art related to the detection and analysis of N-terminal acetylation or deamidation in proteins, particularly in a viral context.

Since I cannot directly access the list of "Cited Patents" or "Cited by" from the Google Patents page or perform a live, deep dive into the USPTO database to extract specific details for each cited reference (like a patent examiner using a dedicated search tool), I will outline the type of analysis that would be performed if those citations were available:

To accurately identify the most relevant prior art and its impact on specific claims, one would need to perform the following steps for each cited reference:

1. Retrieve Full Citation Details: Obtain the complete bibliographic information for each cited patent or publication, including inventors, assignee, filing date, publication date, and abstract.
2. Review Publication/Filing Date: Confirm that the publication or effective filing date of the prior art reference predates the priority date of US12298313B1 (2016-08-15).
3. Summarize Brief Description: Read the abstract and relevant sections of the prior art to understand the disclosed invention or method.
4. Map to Claims of US12298313B1: Carefully compare the teachings of the prior art reference with each independent claim (and its dependent claims) of US12298313B1.
   • For claims 1 and 5 (LC/MS for serotyping/heterogeneity of intact VPs): Look for prior art describing the denaturation of AAV particles followed by LC/MS to determine masses of VP1, VP2, and VP3 for serotype identification or heterogeneity assessment.
   • For claims 9 and 13 (LC/MS/MS for serotyping/heterogeneity of VP fragments): Look for prior art disclosing denaturation, reduction/alkylation, digestion, and subsequent LC/MS/MS analysis of VP fragments for serotype determination or heterogeneity assessment.
   • For claims 17, 22, 23, 24 (AAV particles/methods with altered N-terminal acetylation): Search for prior art discussing amino acid substitutions at position 2 of VP1 and/or VP3 that impact N-terminal acetylation and its effect on assembly, stability, or transduction.
   • For claims 29, 30, 31, 32 (AAV particles/methods with altered deamidation): Look for prior art describing amino acid substitutions at specific residues (A35, N57, G58, N382, G383, N511, G512, N715, or G716) that alter deamidation and its effect on assembly, stability, or transduction.
5. Assess Anticipation under 35 U.S.C. § 102: Determine if every limitation of a given claim in US12298313B1 is disclosed in a single prior art reference. If so, that claim is anticipated. This requires a detailed, element-by-element comparison.

Without direct access to the cited prior art documents, I cannot provide a list of specific citations with detailed descriptions and claim anticipation analysis. However, the keywords and patent description strongly suggest that the core novelty of US12298313B1 lies in the application of advanced mass spectrometry techniques (LC/MS and LC/MS/MS) for detailed characterization of AAV capsids, including post-translational modifications, to determine serotype and heterogeneity. Therefore, any prior art that discloses similar mass spectrometry-based methods for comprehensive AAV characterization, especially predating 2016-08-15, would be highly relevant under 35 U.S.C. § 102.